Related Experiment Video

Updated: Jul 13, 2026

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy
10:02

A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy

Published on: November 3, 2016

Neurological deterioration in late infantile neuronal ceroid lipofuscinosis

S Worgall1, M V Kekatpure, L Heier

  • 1Department of Genetic Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA. geneticmedicine@med.cornell.edu

Neurology
|August 8, 2007
PubMed

Insights

The Weill Cornell scale better assesses late infantile neuronal ceroid lipofuscinosis (LINCL) progression than the modified Hamburg scale. MRI measurements also correlate with disease severity, aiding therapeutic evaluations.

Area of Science:

  • Neurology
  • Pediatric Neurology
  • Neuroscience

Background:

  • Late infantile neuronal ceroid lipofuscinosis (LINCL) is a severe neurodegenerative disorder.
  • It affects the brain and retina, beginning in early childhood.
  • Accurate assessment tools are crucial for monitoring disease progression.

Purpose of the Study:

  • To compare the efficacy of two rating scales for assessing LINCL severity.
  • To evaluate the correlation between CNS imaging findings and disease progression.
  • To determine the utility of these tools for therapeutic strategy evaluation.

Main Methods:

  • Analysis of 32 assessments from 18 children with LINCL.
  • Utilized neurologic, ophthalmologic, and CNS imaging (MRI, MRS) data.
  • Compared a modified Hamburg LINCL scale with the newly developed Weill Cornell LINCL scale.

Main Results:

  • The Weill Cornell scale showed a stronger correlation with age and disease duration than the modified Hamburg scale.
  • No significant differences in scale ratings were found for common CLN2 mutations.
  • MRI and MRS measurements correlated with age and disease duration, and better with the Weill Cornell scale.

Conclusions:

  • The Weill Cornell LINCL scale and specific MRI measurements are valuable for assessing LINCL severity and progression.
  • These tools can aid in evaluating new therapeutic interventions for LINCL.
  • Further research can refine these methods for clinical application.
Abstract

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...